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Water decoction made from the seed of Hunteria umbellata is widely used in the traditional management of diabetes 
mellitus by Nigerian herbalists, particularly, in the southwest region of the country. Recently, a new bisindole alkaloid, erinidine, 
was isolated but its antihyperglycemic profile remains largely un-investigated scientifically. This forms the basis for the current 
study which is primarily designed at investigating the antihyperglycemic profile of erinidine and other fractions in both in vitro 
and in vivo models of diabetes mellitus. In the present study, erinidine was isolated and purified using the earlier described 
methods and its antihyperglycemic potentials tested in in vitro models such as dipeptidylpeptidase (IV), glycogen phosphorylase, 
HIT-T15 cell insulin secretion, glucose uptake activity, aldose reductase assays and α-glucosidase inhibition assay testings. In 
addition, 50 mg/kg of erinidine and that of other fractions were evaluated in in vivo models of normal and chemically-induced 
hyperglycemic rats. Results showed that erinidine was a light yellow, amorphous solid with UV (CHCl3) λmax 256 nm, HRESIMS 
m/z 382.1881 [(M+H)+] (calculated for C22H26N4O2, 382.1876) and melting point of 230 ºC. The in vitro study showed the 
antihyperglycemic action of erinidine to be weakly mediated via α-glucosidase inhibition mechanism as the results for other in 
vitro tests such as dipeptidylpeptidase (IV), glycogen phosphorylase, HIT-T15 cell insulin secretion, glucose uptake activity and 
aldose reductase assays were all negative. However, the in vivo results showed 50 mg/kg erinidine given per os to normal and 
alloxan-induced hyperglycemic rats to significantly (p<0.05, p<0.001) attenuate an increase in their post-absorptive blood glucose 
concentrations after 3 g/kg glucose loading in the rats, suggesting its antihyperglycemic mechanism to be via α-glucosidase 
inhibition. This result, although, further corroborated the in vitro findings but also suggests that erinidine needs to be bio-
transformed in vivo for its inhibitory activity on intestinal glucose absorption to become evident. Thus, the present study suggests 
erinidine to be the possible antihyperglycemic agent in Hunteria umbellata seed extract mediating its antihyperglycemic action 
via intestinal glucose uptake inhibition.  
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Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia and glucose intolerance, either 
due to insulin deficiency or impaired effectiveness of insulin’s action, or to a combination of both factors (Deutschländer, 2009). 
The global prevalence of DM was estimated at 2.8% in 2000 (171 million people) and this is expected to rise to 9.9% (552 million 
people) of adult population by the year 2030 if no urgent efforts are directed at stemming the tide of this global public health 
burden (Whiting et al., 2011). It is also predicted that by 2030, India, China and the United States will have the largest number of 
diabetes sufferers (Wild et al., 2004). However, the burden of the disease is high, not only because life-long treatment is necessary 
but also due to the prohibitive cost and unavailability of orthodox/conventional treatment options in rural areas. In the effective 
management of DM, combination therapy is often employed, particularly, in the management of type 2 diabetes mellitus (Gerich, 
2001). In 2007, World Health Organization reported that one of the strategies to be adopted in combating/stemming the tide of the 
disease is to support research in community interventions, including traditional and herbal medicine, for which reason the search 
for new anti-diabetic agents continues (World Health Organization, 2007). One of such herbal plants used in the local 
management of diabetes mellitus among the Yoruba herbalists in Southwest Nigeria is Hunteria umbellata. 
Hunteria umbellata (K. Schum.) Hallier f. (locally known as “Abeere”) (family: Apocynaceae) is tropical rainforest tree 
which is popularly used for the local management of diabetes mellitus and obesity (Adegoke and Alo, 1986; Falodun et al., 2006; 
Adeneye and Adeyemi, 2009a). In African folk medicine, water decoction made from the dry seeds of Hunteria umbellata is 
employed in the local management of diabetes and obesity (Adegoke and Alo, 1986; Adeneye and Adeyemi, 2009a; Igbe et al., 
2009). The crude aqueous extract of the plant have been shown to possess antihyperglycemic (Adeneye and Adeyemi, 2009a, 
2009b; Igbe et al., 2009), anti-obesity and antihyperlipidemic (Adeneye et al., 2010a), anti-inflammatory and antioxidant 
(Adeneye et al., 2011) with the crude alkaloid fraction found to be its principal antihyperglycemic, anti-inflammatory and 
antioxidant agent (Adeneye et al., 2011; Adeneye et al., 2012a). The aqueous seed extract of the plant has also been reported to be 
relatively safe when administered orally (Ibeh et al., 2007; Adeneye et al., 2010b).  
Recently we isolated a new bisindole alkaloid, erinidine (Figure 1), from the crude aqueous seed and alkaloid extracts of 
Hunteria umbellata (Adeneye et al., 2012b). Literature search indicated that till date, there is no scientific report on the screening 
of antihyperglycemic potential of erinidine. Thus, this forms the basis for the current study which screens erinidine and, indeed 
other fractions, for their possible antihyperglycemic potentials in both in vitro and in vivo models of diabetes mellitus. However, 
the choice of the therapeutic dose (50 mg/kg) of erinidine and other fractions screened was based on results of preliminary test 
earlier conducted. For the purpose of clarity, of the fractions of Hunteria umbellata extract investigated, more emphasis was 



















Figure 1: Chemical structure of erinidine from Hunteria umbellata seed 
 
 
Materials and methods 
Plant materials 
 
Eight fresh mature fruits of Hunteria umbellata were collected from the deciduous forest of Odorasanyin District of 
Ijebu-Igbo in Ogun State, Nigeria, in the month of June 2010. From these, 3 kg of fresh seeds was harvested, rinsed in tap water 
and air-dried at room temperature (25 ± 1 ˚C) for 1 month, protected from direct heat and sunlight. Plant identification and deposit 
of voucher specimen were done as earlier described by Adeneye and Adeyemi (2009a). Two kilogram of the dried seed was 
pulverized into fine powder using Laboratory Hammer Mill at the Department of Plant Sciences, College of Agriculture, 
University of Kentucky, U.S.A. The powdered sample was kept in a thick water- and air-proof transparent white polythene bag 












Aqueous extraction process  
 
60 g of the pulverized Hunteria umbellata seed was completely cold extracted in 1L of distilled water after dissolving it 
in distilled water and kept in the refrigerator for 72 hours. The solution was continuously stirred using magnetic stirrer for 6 hours 
after which it was filtered using ®Celite (Analytical filter-aid)-packed filter funnel. The deep brown filtrate was completely dried 
in vacuo using a freeze dryer (LABCONCO ®FreeZone 18 Liter Console Freeze Dry Systems, Labconco Corporation, Kansas 
City, MO, USA) to give a deep brown, sweet-smelling fluffy residue. This procedure was repeated for 6 more times and the 
residues were pooled into a water- and air- proof container and kept in the freezer to prevent decomposition of the extract. 
 
Isolation of erinidine 
 
10 g of Hunteria seed water extract (HU) in 10 ml of distilled water (pH = 4.2) was repeatedly titrated with 50 ml of 5% 
aqueous HCl solution (Aldrich-Sigma, St. Louis, MO, U.S.A.) to acidify the solution to a pH of 2. The acidify solution was 
extracted with ethyl acetate (150 ml x 3) to remove the neutral compounds (HUn) in the acidify HU solution. The acidify HU 
solution was then carefully basified with 5% sodium bicarbonate (Na2CO3) (Aldrich-Sigma, St. Louis, MO, U.S.A.) solution to a 
pH of 10. Using a 5 L separating funnel, the mixture was repeatedly extracted with small portions of ethyl acetate (Aldrich-Sigma, 
St. Louis, MO, U.S.A.) (150 ml x 3) until the last extract was colourless and the basic solution gave negative tests with alkaloid 
detecting (Draggendorff’s) reagents. The ethyl acetate extract obtained was evaporated to complete dryness using rotary 
evaporator coupled with a water bath (®BUCHI Rotavapor Model R-215, BUCHI Labortechnick AG, Flawil, Switzerland) preset 
at 40 °C to give the alkaloid fraction (HUAf) (a yellow-brown solid residue) weighing 0.81 g (yield: 8.10%). HUn solution was 
also completely dried off using this same procedure described for HUAf giving a chocolate-colour fine powder weighing 0.378 g 
(yield: 3.78%). This procedure was repeated five times.  The HUn and HUAf were separately pooled into tight-capped containers 
which were stored in the refrigerator until required for experiment.   350 mg of HUAf was column purified on silica gel flash 
column into 40 fractions using DCM (Sigma Chemical Co., St. Louis, MO, USA) and MeOH (Sigma Chemical Co., St. Louis, 
MO, USA) solvent system (5:1) to obtain fractions 16-25 which were of similar chromatographic pattern were pooled and 
completely dried in vacuo using rotor evaporator, yielding a pale yellow powder (erinidine). This procedure was repeated for 10 




The melting point of alkaloid fractions 16-25 (erinidine) was determined using Fisher-Johns Melting Point Apparatus 
(Thermo Fisher Scientific, Park Lane Drive, Pittsburgh, U.S.A.). IR spectra were recorded on a Shimadzu FT IR 8300 
spectrophotometer (Vmax in cm-1, using KBr pellets) while its LC-MS studies were done on ®Agilent 6200 Series Time-of-Flight 
LC-MS Systems (Agilent Technologies, Elmhurst, Illinois, U.S.A). Erinidine was re-dissolved in dry deuterated chloroform 
(Cambridge Isotope Labs DLM-7) and its 1H NMR spectra were collected at 600 MHz for 1H on a Varian-Agilent INOVA 
spectrometer equipped with a 5 mm bioprobe at 30 °C. 13C spectra were collected at 100 MHz for 13C on a Varian-Agilent 
INOVA Spectrometer equipped with a 5 mm ASW probe (automatic switchable) at 30 °C and 9 kHz 1H decoupling. Chemical 
shifts are reported in parts per million (ppm) relative to TMS in deuterated CHCl3 solution. High resolution electron impact 
ionization mass spectra (HRESIMS) were recorded at 25 eV on a JEOL JMS-700T MStation (magnetic sector instrument) at a 
resolution of greater than 10000. Samples were introduced via heatable direct probe inlet and Perfluorokerosene (pfk) was used to 
produce reference masses. 
 
In vitro antihyperglycemic studies of erinidine 
Alpha glucosidase assay 
 
Alpha-glucosidase from Baker’s yeast (Type I) and p-nitrophenyl-D-glucopyranoside (pNPG) were purchased from 
Sigma Chemical Co. (St. Louis, MO, USA). Other reagents were of analytical grade and were used without further purification. 2 
µL of 1–2.5 U/mL of alpha-glucosidase {from Baker’s yeast (Type I)} was premixed with 20 µL of erinidine at varying 
concentrations and incubated for 5 min at 37 oC. 20 µL of 1 mM pNPG (Sigma Chemical Co., St. Louis, MO, USA) in 50 mM of 
phosphate buffer was added to initiate the reaction, and the mixture was further incubated at 37 oC for 20 min. The reaction was 
terminated by the addition of 50 µL of 1M Na2CO3, and the final volume was made up to 150 µL. Alpha glucosidase activity was 
determined spectrophotometrically at 405 nm on a Biorad 550 microplate reader (Hercules, California, U.S.A.) by measuring the 
quantity of p-nitrophenol released from pNPG. The assay was performed in triplicate with appropriate blanks and controls.   
 
Dipeptidylpeptidase-IV (DPP-IV) assay 
 
DPP-IV, Gly-Pro-4-Nitroanilide, Diprotin A (positive control) and Trizma base were purchased from Sigma-Aldrich 
Chemical Co. (St. Louis, MO, USA). The 96 well plates were purchased from VWR International Inc. The 96 well plate reader 
was purchased from Bio-Rad Laboratories, Inc. (Richmond, CA, USA). 6.5 mg of erinidine was weighed and dissolved in 13 ml 
0.1 M Tris:DMSO (1:1) at pH 8.0  to produce a 0.5 mg/ml solution. Serial dilutions of the sample were made in PBS (0.250, 






















Tris buffer.  One unit will produce 1 μmol of p-nitroaniline from Gly-Pro-p-nitroanilide per min in 0.1 M Tris buffer 
(pH = 8.0) at 37 ºC.  A 1 mM stock solution of Gly-Pro-p-nitroanilide (M.W. 328.75; Sigma Aldrich chemicals, St. Louis, MO, 
U.S.A.) was prepared at pH 8.0 with 0.1 M Tris buffer. The assay was run by mixing 15 μL of 0.1 M Tris buffer, 25 μL of 
enzyme solution and 10 μL of control or erinidine samples. Then the mixture was incubated at 37 ºC for 5 min. After that 50 μL 




substrate. The reaction mixture was incubated at 37 ºC for 15 min. The reaction was terminated by adding 25 μL of 25% acetic 
acid to the appropriate wells. The absorbance of the resulting end product was measured at 405 nm. The assay was performed in 
triplicate with appropriate blanks and controls.   
 
Glycogen phosphorylase assay 
  
 6.5 mg of erinidine was weighed and dissolved in 6.5 ml of PBS, and the sample was not soluble (1 mg/ml). 6.5 ml of 
DMSO was added and the sample was soluble (0.5 mg/ml). Then two times and four times dilutions of the sample were made in 
PBS to get 0.250 mg/ml, 0.125 mg/ml of erinidine sample. The cuvette containing 2.7 ml of cocktail, 0.1 ml of glucose-6-
phosphate dehydrogenase (1 unit), 0.1 ml of Phosphoglucomutase (PGLUM) (1 unit), 0.1 ml of DMSO (25% or 12.5%), and 0.1 
ml of glycogen phosphorylase a (Gpa), to a final volume of 3.1 ml, was read against a reference cuvette containing 0.1 ml of 
diluent instead of Gpa. This serves as the negative control. The sample cuvette containing 2.7 ml of cocktail, 0.1 ml of glucose-6-
phosphate dehydrogenase (1 unit), 0.1 ml of PGLUM (1 unit), 0.1 ml of erinidine solution was dissolved in 25% or 12.5% DMSO 
(0.250 mg/ml or 0.125 mg/ml), and 0.1 ml of glycogen phosphorylase a (Gpa), to a final volume of 3.1 ml, was read against a 
reference cuvette containing 0.1ml of diluent instead of Gpa. This is used to test the inhibitory activity of erinidine sample on 
Gpa. The enzymatic reaction was started by the addition of the Gpa and absorbance was recorded at 340 nm for 10 min at 60 s 
interval. Glycogen phosphorylase activity was expressed as change in units/ml/min of enzyme and erinidine inhibitory activity 
also takes into consideration of the negative control. 
 
Insulin secretion in cultures of HIT-T15 cells 
 
HIT-T15 cells and tissue labware which were used for this study were purchased from VWR (West Chester, PA, USA). 
All other reagents used were of analytical grade and purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). 5.0 mg of 
erinidine was weighed and dissolved in 5.0 ml dimethyl sulfoxide (DMSO) to a concentration of 1 mg/ml. and then diluted in 
Hank’s balanced salt solution (HBSS) to obtain 0.25 mg/ml and 0.125 mg/ml samples. 25% and 12.5% DMSO in HBSS were 
used as blank. Samples were filtered through 0.45 μm sterile filters. HIT-T15 cells were seeded into collagen-coated sterile 96-
well plates at a density of 7.5×104 cells per well. The HIT-T15 cells were cultured in 200 µl in 300 cm3 vented cap tissue culture 
flasks using Hams F-12K modified nutrient mixture supplemented with 10 % dialyzed horse serum (Life Technologies, Rockville, 
MD, USA) and 2.5 % bovine fetal serum (Life Technologies, Rockville, MD, USA). The cells in the plate were incubated and 
maintained at 37 °C for 24 hr in an atmosphere of humidified air and CO2 (95:5) to allow for cell attachment and recovery. The 
plate with attached cells was removed from the incubator. The spent medium was aspirated and replaced with 200 µl of HBSS, 
which was removed and replaced with fresh 100 µl of HBSS. The cells were incubated for 30 min at 37 °C. Then 100 µl of blank 
and sample were added to wells after HBSS was removed from wells. The plate was incubated for 1 hr and resulting insulin 
concentrations in individual wells were quantified using insulin enzyme-linked immunosorbent assay (ELISA) kit (American 
Laboratory Products Co., Windham, NH, USA) according to the manufacturer’s recommendations. The potential loss of cells due 
to multiple liquid aspiration/dispensing cycles was evaluated by counting the cells in randomly selected wells following 
completion of the incubation. The effect of erinidine on HIT-T15 cell membrane permeability and integrity was assessed by the 
Tryptan Blue method. Upon completion of inhibition, a diluted solution of Tryptan Blue was added to the selected wells. Stained 
and colorless cells were counted under a microscope, the objective of which was fitted with a counting field frame (Rotshteyn and 
Zito, 2004). 
 
Glucose uptake activity assay 
 
Glucose uptake activity was analyzed by measuring the uptake of 2-deoxy-D-[3H] glucose. The confluent 3T3-L1 adipocytes 
grown in 24-well plates were washed three times with serum-free Dulbecco’s Modified Eagle Medium (DMEM) and incubated 
with 1 ml of the same medium at 37 °C for 2 hr. The cells were washed 3 times with Dulbecco’s phosphate buffer saline (DPBS) 
and incubated with 0.8 ml DPBS at 37 °C for 30 min. 0.1 ml DPBS (control), Insulin (10 µM) and test compound were then 
added and adipocytes were incubated at 37 °C for 10 min. Glucose uptake was initiated by the addition of 0.1ml of 10 µCi/ml 2-
deoxy-D-[3H] glucose in DPBS, and 2-deoxy-D-[3H] glucose was 1 µCi/ml as final concentrations. After 10 min, glucose uptake 
was terminated by washing the cells 3 times with cold phosphate buffer saline (PBS). The cells were lysed with 0.7 ml of 1 % 
Triton X-100 at 37 °C for 60 min, shaking every 20 min to make sure the cells were fully lysed. The radioactivity retained by the 
cell lysate was determined by a scintillation counter with a scintillation fluid, ScintiSafe 30% cocktail. 
.  
Aldose reductase assay 
 
6.5 mg of erinidine was weighed and dissolved in 13 ml of 50 mM PBS:DMSO (1:1) at pH of 6.8 to produce a 0.5 
mg/ml solution. Serial dilutions of the sample were made in PBS (0.250, 0.125, 0.063, 0.031 and 0.008 mg/ml). Six rat lenses 
were pooled and 10% homogenate was prepared in 0.1M phosphate buffer saline (pH=7.4). After centrifugation at 5000 g for 10 
min, the supernatant was collected and kept in ice to determine aldose reductase activity. The assay procedure adopted is 
summarized below as follows: A sample cuvette containing 0.7 ml of phosphate buffer (0.1 M), 0.1 ml of NADPH(25 x 10-5M), 
0.1 ml of lens supernatant, 0.1 ml of DL-Glyceraldehyde (5 x 10-4M) to a final volume of 1 ml was read against a reference 




absorbance was recorded at 340 nm for 7 min at 30 s interval. Aldose reductase activity was expressed as change in 
absorbance/min/mg of protein. 
 
In vivo antihyperglycemic studies 
Experimental Animals 
 
A total of one hundred and twenty young adult male Wistar rats (weight range: 210-250 g) were obtained in 3 batches 
after ethical approval (UK IACUC no.: 2010-077) has been obtained from the Institutional Ethical Committee on the Use of 
Experimental Animals in University of Kentucky, U.S.A. The rats were acclimatized for 7 days, fed on standard rat chow and tap 
water ad libitum. The rats were housed in a standard rat cages in the Animal Facility of the College of Pharmacy, University of 
Kentucky,  and maintained at standard laboratory conditions (12/12 hr light-dark periodicity, temperature: 23-26 ˚C) as prescribed 
by the United States National Institute for Health (1985). Two days prior to commencement of the experiment, rats were 
randomly divided into 6 groups of 6 rats per treatment group such that the weight differences within and between treatment 
groups do not exceed ±20% of the average weight of the rat population, respectively. 
 
Oral glucose tolerance test in normal rats 
 
Rats were fasted overnight for 12-14 hr prior to commencement of the animal experiment. Their baseline fasting blood 
glucose values were obtained before oral treatment with the drugs or β-D (+) glucose (97+ %) anhydrous (Sigma Chemical 
Company, St. Louis, MO, USA) dissolved in 10 ml/kg distilled water-Tween 80 (9:1). Group I rats, which served as the untreated 
control, were orally pretreated with 10 ml/kg 10% Tween 80-distilled water 1 hr before treatment with another 10 ml/kg per os 10 
% Tween 80-distilled water. Group II rats served as the model control and were pretreated with 10 ml/kg per os 10% Tween 80-
distilled water 1 hr before oral treatment with 3 g/kg D-glucose. Groups III - VI rats which served as the treatment groups were 
orally pretreated with 50 mg/kg HU, HUAf, HUn and erinidine, respectively, for 1 hr before the oral administration of 3 g/kg D-
glucose, as described by Sepici et al. (2004) and Adeneye and Adeyemi (2009a). The choice of 10% Tween 80-distilled water as 
the vehicle was made because the test compounds-HUAf, HUn and erinidine were incompletely soluble in distilled water alone.  
 
Oral glucose tolerance test in alloxan-induced hyperglycemic rats 
 
Following a 24-hr fast, rats were made hyperglycemic by injecting each rat with a single intraperitoneal dose of 120 
mg/kg of alloxan monohydrate (Sigma Chemical Company, St. Louis, U.S.A.) dissolved in 3 mM of freshly prepared cold citrate 
buffer (pH = 4.5). The baseline fasting blood glucose was first determined before alloxan treatment. Six hours after alloxan 
injection, rats were orally infused with 20% Dextrose (Unique Pharmaceuticals, Sango-Otta, Ogun State, Nigeria) at an oral dose 
of 10 ml/kg so as to prevent the onset of fatal hypoglycemia which often accompanies administration of alloxan as a result of 
acute massive pancreatic release of insulin (Prince and Menon, 2001). Gradual onset of hyperglycemia was confirmed on the 3rd 
day post-induction but a steady hyperglycemic state was achieved by the 5th day post-alloxan treatment. By the 5th day, rats with 
fasting blood glucose of equal or greater than 200 mg/dl were considered hyperglycemic. Six normal and thirty-six alloxan-
induced hyperglycemic rats were randomly allocated into 7 treatment groups as follows: 
Group I consists of normoglycemic rats which were orally treated with 10 ml/kg 10% Tween 80-distilled water 1 hr before 
treatment with another 10 ml/kg per os 10 % Tween 80-distilled waater; 
Group II consists of alloxan-induced hyperglycemic rats orally treated with 10 ml/kg 10% Tween 80-distilled water 1 hr before 
treatment with another 10 ml/kg per os 10 % Tween 80-distilled water; 
Group III consists of alloxan-induced hyperglycemic rats orally pre-treated with 10 ml/kg 10% Tween 80-distilled water 1 hr 
before treatment 3 g/kg D-glucose dissolved in 10 % Tween 80-distilled water; 
Groups IV-VII consist of alloxan-induced hyperglycemic rats that were orally pre-treated with 50 mg/kg HU, HUAf, HUn and 
erinidine, respectively, for 1 hr before the oral administration of 3 g/kg D-glucose, as described by Sepici et al. (2004) and 
Adeneye and Adeyemi (2009a). The blood glucose levels were determined at 30 min interval over the period of 4 hours. 
 
Adrenaline-induced hyperglycemia test 
 
This phase of animal studies also involved the use of 36 normoglycemic adult male Sprague-Dawley rats. Rats were 
fasted overnight for 12-14 hr prior to commencement of this phase of animal experiment. The rats’ baseline fasting blood glucose 
values were obtained before oral treatment with the extracts or intraperitoneal injection of 50 μg/kg of adrenaline (Sigma 
Chemical Company, St. Louis, MO, U.S.A.) dissolved in 1 ml/kg 10% Tween 80-distilled water. Group I rats, which served as the 
untreated control, were orally pretreated with 10 ml/kg 10% distilled water-Tween 80 1 hr before intraperitoneal injection of 1 
ml/kg of 10% Tween 80-distilled water. Group II rats served as the model control and were pretreated with 10 ml/kg per os 10% 
Tween 80-distilled water 1 hr before intraperitoneal injection of 50 µg/kg adrenaline. Groups III - VI rats which served as the 
treatment groups were orally pretreated with 50 mg/kg HU, HUAf, HUn and erinidine, respectively, for 1 hr before intraperitoneal 







Blood glucose measurements 
 
Following administration of hyperglycemia-induced agents, whole blood glucose levels were collected at 0 min, 30 min, 
60 min, 90 min, 120 min, 150 min, 180 min, 210 min and 240 min by tail tipping method at between 08:00 and 12:00 hr. The 
glucose levels were measured by glucose oxidase method of Trinder (1969) using ®TheraSense FreeStyle Flash Glucose Meter 
(Model: T-H010-64110, TheraSense Inc., Alameda, California, U.S.A.). The blood glucose meter was calibrated and validated at 




Results were presented as mean ± S.E.M. of six observations. Statistical analysis was done using two-way analysis of 
variance followed by post-hoc test, Student-Newman-Keuls test on SYSTAT 10.6. Statistical significance were considered at 




Extraction and chromatographic studies on erinidine 
 
The alkaloid fractions 16-25 (erinidine) was a light yellow, amorphous solid with UV (CHCl3) λmax 256 nm; IR (KBr) 
νmax 3273, 2940, 2872 and 1734 cm
-1(Figure 2), HRESIMS m/z 382.1881 [(M+H)+] (calculated for C22H26N4O2, 382.1876), 
melting point of 230 ºC, full mass spectroscopy (Figure 3) and LC/MS pattern (Figure 4). 
 
In vitro antihyperglycemic studies of erinidine 
Alpha glucosidase assay 
 
The inhibition of α-glucosidase by treatment with 0.016-0.25 mg/ml of erinidine is given in Table 1. The % inhibition of 
erinidine on α-glucosidase ranges from 0.25 % (for 0.016 mg/ml) to 28.17 % (for 0.25 mg/ml) and these inhibitory effects are 
considered non-significant (Table 1). 
 
Table 1: Inhibitory effect of 0.008-0.25 mg/ml of erinidine on α-glucosidase 
______________________________________________________________________________  
Erinidine concentration (mg/ml)                   Percentage (%) inhibition 
______________________________________________________________________________ 
0.250        28.170      
0.125        8.370 
0.063        8.240 
0.031        2.910 
0.016        2.280 
0.008        0.250 
______________________________________________________________________________  
 
Table 2: Inhibitory effect of 0.008-0.25 mg/ml of erinidine on DPP-IV assay 
____________________________________________________________________________________  
Erinidine concentration (mg/ml)     Percentage (%) Inhibition 
____________________________________________________________________________________  
0.250        3.170 
0.125        1.370 
0.063        0.000 
0.031        0.000 
0.016        0.000 
0.008        0.000 






Inhibition of DPP-IV by treatment with 0.008-0.25 mg/ml of erinidine is given in Table 2. The inhibitory values  
obtained for erinidine range from 0.00 % (for 0.008 mg/ml) to 3.17 % (for 0.25 mg/ml) concentration which is considered as a 






Table 3: Inhibitory effect of 0.125 and 0.250 mg/ml of erinidine on glycogen phosphorylase 
______________________________________________________________________________  
Erinidine concentration (mg/ml)                         Percentage (%) Inhibition on 
______________________________________________________________________________ 
0.250        0.000 




Table 4: Insulin secretory effect of 0.125 and 0.25 mg/ml of erinidine on HIT-T15 cells  
______________________________________________________________________________  
Erinidine concentration (mg/dl)  Insulin concentration (ng/ml) 
______________________________________________________________________________  
0.125       0.070 




Table 5: Inhibitory effect of 0.008-0.125 mg/ml of erindine on aldose reductase activity  
______________________________________________________________________________  
Erinidine concentration (mg/dl)  % inhibition on aldose reductase activity 
______________________________________________________________________________  
0.125        0.000 
0.062        0.000 
0.031        0.000 
0.016        0.000 
0.008        0.000 





Glucose uptake activity assay 
 
Similar non-significant effect (p>0.05) with erinidine was recorded in the glucose uptake test when compared to the 
control (DPBS) (Figure 6 and Table 3).  
 
Effect of erinidine on insulin secretion in cultures of HIT-T15 cells 
 
In order to evaluate the secretory potential of erinidine on HIT-T15 cells, the cell cultures were incubated with varying 
amounts of erinidine and measured the amount of insulin secreted Results showed that treatment with 0.125 and 0.25 mg/ml of 
erinidine did not cause any significant (p>0.05) increase in insulin secretion when compared to the buffer control (Figure 5 and 
Table 4). In addition, there was no detrimental effect on cell viability or membrane integrity by the varying concentrations of 
erinidine used as determined by the Tryptan Blue exclusion method. The cell viability was at least 95 % in all experimental 
groups including control. 
 
Aldose reductase assay 
 
In the aldose reductase assay, five different concentrations ranging from 0.125 mg/ml to 0.008 mg/ml were tried and 
none of the concentrations used was effective in the assay (Table 5). However, treatment with 0.1 mg/ml of Epilrastat (standard 
control) resulted in 87.00 % inhibition of aldose reductase enzyme (Table 5). 
 
 
In vivo antihyperglycemic studies 
Oral glucose tolerance test in normal rats 
 
Single oral administration of 3 g/kg of glucose dissolved in 10% Tween 20-distilled water resulted into a significant 
(p<0.05) postpandrial hyperglycemia within 30 min postpandrial, reaching its peak at 90 min and gradually decreases from 180 
min and subsequently returned to about normal value from 150 min to 240 min postpandrial (Table 6). Oral pretreatment with 50 
mg/kg of HU, HUAf and erinidine significantly (p<0.05) attenuated a rise in postpandrial hyperglycemia within 60 min of glucose 
administration and blood glucose levels significantly (p<0.05, p<0.001) and time-dependently decreasing from 90 min to 240 min 




postpandrial blood glucose levels and ultimately induced hypoglycemia, these biological effects were lower than  that recorded 
for HUAf. However, HUn neither prevented postpandrial glucose rise within 60 min of its administration nor subsequently lower 













Table 6: Effect of 50 mg/kg of HU, HUAf, HUn and erinidine on blood glucose (BG) levels in glucose-induced hyperglycemic 
rats 
___________________________________________________________________________________________  
Time (min)    Blood glucose levels (mg/dl) of treatment groups 
  ---------------------------------------------------------------------------------------------------------------------- 
  I  II  III  IV  V  VI       
___________________________________________________________________________________________   
0 53.0 ± 1.3 54.3 ± 3.1 54.7 ± 3.1 57.7 ± 2.2 56.3 ± 1.1 55.7 ± 2.2                                
30 69.7 ± 4.4 93.3 ± 8.4a 65.7 ± 2.4b 65.0 ± 2.7 b 90.7 ± 4.4a 64.7 ± 1.1b 
60  66.0 ± 4.0 97.7 ± 2.4a 64.3 ± 2.2b 67.3 ± 1.8b 82.7 ± 4.9a 70.7 ± 1.8b 
90 64 ± 2.7  89.7 ± 3.1a 61.0 ± 2.0b 62.7 ± 3.6b 81.7 ± 3.6a 74.3 ± 3.1 
120 59.7 ± 6.4 77.0 ± 6.7a 58.7 ± 2.2b 59.7 ± 2.4b 83.0 ± 2.7a 67.3 ± 3.8b 
150 60.7 ± 5.8 81.3 ± 19.1a 55.7 ± 1.1b 57.7 ± 2.8c 70.0 ± 6.7 60.3 ± 3.1b 
180 60.3 ± 4.9 69.7 ± 4.4b 54.3 ± 2.9b 56.7 ± 4.9c 74.3 ± 5.1 59.3 ± 4.9b    
210 56.3 ± 4.4 65.3 ± 2.2b 51.3 ± 2.2b 50.7 ± 3.6c 73.0 ± 8.7 54.3 ± 5.6c 
240 55.0 ± 6.7 61.7 ± 4.2b 49.3 ± 3.1b 49.0 ± 5.3c 76.3 ± 9.1 48.7 ± 5.1c 
_____________________________________________________________________________________________ 
a represents a significant increase at p<0.05 when compared to the basal value at 0 min while b and c represent significant 
decreases at p<0.05 and p<0.001 when compared to 30 min and 60 min values for Group II. 
Group I: 10 ml/kg of 10% Tween 80-DW 
Group II:  10 ml/kg of 10% Tween 80-DW + 3 g/kg of D-Glucose in 10% Tween 80-DW 
Group III: 50 mg/kg HU in 10% Tween 80-DW + 3 g/kg of D-Glucose in 10% Tween 80-DW 
Group IV: 50 mg/kg of HUAf in 10% Tween 80-DW + 3 g/kg of D-Glucose in 10% Tween 80-DW 
Group V: 50 mg/kg of HUn in 10% Tween 80-DW + 3 g/kg of D-Glucose in 10% Tween 80-DW 







Figure 5: Standard curve for the insulin secretion by the HIT-T15 cells 
 
 
Figure 6: Glucose uptake ratio of erinidine (test compound) relative to that of the control buffer solution showing no significant 












































Figure 7: Effect of 50 mg/kg HU, HUAf, HUn and erinidine on the postpandrial blood glucose concentrations in alloxan-induced 
hyperglycemic rats 
a, b and c represent significant increases in postpandrial glucose concentrations at p<0.05, p<0.01 and p<0.001, respectively, when 
compared to the basal values at 0 min while d, e and f represent significant decreases at p<0.05, p<0.01 and p<0.001 in the 
postpandrial glucose concentrations when compared to values at 60 min.  
I = normoglycemic rats + 10 ml/kg of 10 ml/kg of 10%Tween 80-distilled water p.o. ; II = alloxan-induced hyperglycemic rats + 
10 ml/kg 10%Tween 80-distilled water p.o. pretreatment + 3 g/kg of D-glucose p.o.; III = alloxan-induced hyperglycemic rats + 
50 mg/kg HU in 10%Tween 80-distilled water p.o. pretreatment + 3 g/kg of D-glucose p.o.; IV = alloxan-induced hyperglycemic 




hyperglycemic rats + 50 mg/kg HUn in 10%Tween 80-distilled water p.o. pretreatment + 3 g/kg of D-glucose p.o.; VI = alloxan-
induced hyperglycemic rats + 50 mg/kg erinidine in 10%Tween 80-distilled water p.o. + 3 g/kg of D-glucose p.o. 
 
 
Figure 8: Acute time-course effect of 50 mg/kg HU, HUAf, HUn and erinidine pre-treatment on blood glucose levels in 
adrenaline-induced hyperglycemic rats 
a, b and c represent a significant rise at p<0.05, p<0.01 and p<0.001 when compared to the basal value at 0 min. 
I = 10 ml/kg 10%Tween 80-distilled water p.o. + 1 ml/kg of 10%Tween 80-distilled water i.p.; II = 10 ml/kg 10%Tween 80-
distilled water p.o. + 50 µg/kg adrenaline i.p.; III = 50 mg/kg HU in 10%Tween 80-distilled water p.o. + 50 µg/kg adrenaline i.p. 
IV = 50 mg/kg HUAf in 10%Tween 80-distilled water p.o. + 50 µg/kg adrenaline i.p.; V = 50 mg/kg HUn in 10%Tween 80-
distilled water p.o. + 50 µg/kg adrenaline i.p.; VI = 50 mg/kg erinidine in 10%Tween 80-distilled water p.o. + 50 µg/kg 
adrenaline i.p. 
 
Oral glucose tolerance test in alloxan-induced hyperglycemic rats 
 
By the 5th day following single intraperitoneal injection with 120 mg/kg of alloxan, hyperglycemia became fully 
established in the treated rats. Oral treatment of alloxan-induced hyperglycemic rats with 3 g/kg of D-glucose was associated with 
significant (p<0.01, p<0.001) rise in the blood glucose levels at 30 min which peaked at 60 min and remained significantly high 
up to 240 min postpandrial in Group II rats (Figure 7). However, pretreatment with 50 mg/kg of HU, HUAf and erinidine was 
associated with varying and significant (p<0.05, p<0.01 and p<0.001) attenuation of increases and eventual decreases in the 
postpandrial blood glucose levels, with erinidine exhibiting the most significant hypoglycemic effect in the treated alloxan-
induced hyperglycemic rats (Figure 7). HUn caused no significant alterations in the postpandrial blood glucose levels. 
 
Adrenaline-induced hyperglycemia studies 
 
Intraperitoneal injection of 50 µg/kg of adrenaline to rats pre-treated with 10 ml/kg of 10% Tween 80-distilled water 
resulted in significant (p<0.001) elevation in the blood glucose levels from 78.00 mg/dl at 30 min and peaking at 113.00 mg/dl at 
60 min post-injection (Figure 8). The elevated blood glucose levels then gradually decreased from 98.33 mg/dl at 90 min to 81.67 
mg/dl at 240 min (Figure 8). Oral pre-treatment with 50 mg/kg of HU and HUAf attenuated a noticeable elevation in the blood 
glucose levels following intraperitoneal administration of 50 µg/kg of adrenaline (Figure 8). However, oral pre-treatment with 








The physico-chemical property of erininide isolated and other fractions of HU obtained in this study appear to be the  
same with those previously reported by Adeneye et al. (2012b Bioengineered cell culture lines such as RIN β-cell, HIT-T15, β-
TC-6, MIN6, INS-1 and 3T3-L1 cells have been used to establish and facilitate studies of mechanisms of both insulin secretion 
and β-cell dysfunction, being also the target to the study of natural products (Poitout et al., 1996; Maddux et al., 2001; Karalee et 
al., 2001). These cell lines release mainly insulin and small amounts of glucagon and somatostatin. Although the behavior of none 
of these cell lines perfectly mimics primary β-cell physiology, they are extremely valuable tools for the study of molecular events 
underlying β-cell function (Persuad et al., 1999; Frӧde and Medeiros, 2008). Other in vitro antihyperglycemic screening 
techniques such as alpha-glucosidase inhibition, DPP-IV inhibition, glycogen phosphatase inhibition, and aldose reductase 
inhibition have been designed to simulate specific events occurring at the molecular, cellular and sub-cellular levels in the 
pancreatic β-cell and as such could serve as an alternative or complement to in vivo models (Fujita et al., 1996; Gerbhardt, 2000; 
Rotshteyn and Zito, 2004). These screening techniques usually offer fast, reliable and cost-effective screening alternative in 
addition to requiring only very small amounts of experimental compound, and minimal technicalities (Rotshteyn and Zito, 2004). 
In the present study, insulin-secretion property of 0.125 and 0.250 mg/ml of erinidine was studied using HIT-T15 cell culture, 
with erinidine failing to increase insulin secretion in the cultured cells suggesting that erinidine may unlikely possess 
sulfonylurea-like activity. This observation is in complete agreement with earlier report that the crude water seed extract of 
Hunteria umbellata does not mediate antihyperglycemic action via hyperinsulinemia mechanism (Adeneye and Adeyemi, 2009a; 
Adeneye and Adeyemi, 2009b).  
In the in vivo screening of erinidine and other fractions of HU for their possible antihyperglycemic potential, 
intraperitoneal adrenaline was used to induce acute hyperglycemia in the treated Spargue-Dawley rats. Adrenaline produces 
hyperglycemia by inhibiting insulin release, stimulating glycogenolysis in muscle and thus providing substrate in the form of 
lactate for hepatic gluconeogenesis, stimulating glucagon secretion and stimulating ACTH secretion which, in turn, stimulates 
glucocorticoid secretion from the adrenal cortex (Kraus-Friedmann, 1984; Krusteva, 1992; Alada et al., 2001). However, the test 
compounds did not significantly reduce the adrenaline induced hyperglycemia suggesting that they probably do not mediate their 
action via inhibition of adrenaline-induced stimulation of α2 receptors in β-cells of pancreas and thus promoting hyperinsulinemia. 
Acute transient hyperglycemia is known to occur following absorption of glucose into the porta blood from the gastro-intestinal 
tract after oral ingestion of a meal. This post-absorptive hyperglycemia is often accompanied by hyperinsulinemia, particularly 
within the first few hours postpandrial. This physiological response is aimed at lowering the postpandrial hyperglycemia and 
maintains it within normal range, as insulin is known to promote intracellular glucose transport. However, this mechanism is very 
unlikely for this experiment as the injected alloxan (a potent cytotoxin) would have destroyed the pancreatic β-cells to a large 
extent for hyperglycemia to become established. It is, thus, plausible that erinidine and other fractions could be mediating their 
antihyperglycemic effects via inhibition of intestinal glucose uptake and improvement in the oral glucose tolerance in the treated 
rats, an action similar to those of standard alpha glucosidase inhibitors such as acarbose, miglitol and voglibose. Although, results 
of the in vitro studies showed erinidine to have a weak alpha glucosidase inhibition property but produced a significant intestinal 
glucose uptake inhibitory effect in vivo. This observation further suggests that erinidine may require biotransformation to its 
active metabolite(s) for its glucose uptake inhibitory effect to manifest. This observation may be explained by the fact that some 
extracts may not show good biological activities in in vitro assay but may become pharmacologically active after undergoing in 
vivo metabolism into their active metabolites (Farnsworth, 1993). Further studies are currently underway to provide insight into 
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